Tolebrutinib

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.